CAR T Cell Therapy Patent - US12600775B2

USPTO granted Patent US12600775B2 to Kite Pharma, Inc. for chimeric antigen receptor T cell therapy inventions. The patent covers methods for preparing, producing, processing, culturing, isolating, or making cells suitable for immune or cell therapy, and their use in cell therapy applications. The patent contains 9 claims and is classified under multiple CPC codes including A61K, C07K, and C12N categories related to cancer treatment.

For pharmaceutical companies and biotech firms developing cell therapies, this patent establishes intellectual property protection around CAR T cell preparation and use methods. Competitors developing similar cell therapy approaches may need to evaluate freedom-to-operate considerations or explore licensing opportunities with Kite Pharma.